



INDIAN PHARMACOPOEIA COMMISSION

(Ministry of Health & Family Welfare, Government of India)

Sector-23, Raj Nagar, Ghaziabad 201 002.

Tel No: +91-120-2783392, 2783400, 2783401

E-mail: lab.ipc@gov.in, Web: www.ipc.gov.in

Date: 29.03.2020

To,
All the Stakeholders of IPC

NOTICE

We all are aware that Novel Coronavirus Disease (COVID-19) outbreak has been declared as pandemic by the World Health Organization and in order to protect the country and each of its citizens, Hon'ble Prime Minister of India has announced 21-day nationwide lockdown on 24th March, 2020. Being an autonomous Institute under the Ministry of Health & Family Welfare, Government of India, the Indian Pharmacopoeia Commission (IPC) is actively engaged in providing important healthcare related services to the country. In order to better serve the nation during this health emergency situation due to COVID-19, IPC would continue to operate with minimal essential staff offering following services to its stakeholders:

1. IPC has been continuing with supplying the Indian Pharmacopoeia Reference Substances (IPRS) and Impurity Standards to all the stakeholders including drug manufacturers and drug testing laboratories so that there is no hurdle in testing of medicines for their release into the market.
2. IPC is extending its support of analytical laboratories for test and analysis of the drugs received from various government agencies for their quality control purposes. Also, we are committed to test analyze any New Drug Substances received through Drug Regulatory Agencies for their marketing authorization in India and any drug related to COVID-19 would be given top priority in such cases.
3. We are also offering our analytical laboratory services to drug manufacturers and research laboratories for the R&D of pharmaceuticals particularly to combat the COVID-19. Details of these services are available on our website.
4. Technical queries related to the Indian Pharmacopoeia (IP) monographs received from stakeholders will continue to be addressed by IPC after consultation with the Expert Working Groups members through electronic means.
5. Stakeholders should continue to report suspected Adverse Drug Reactions, if any, noticed with the use of Medicines or Medical Devices to our PvPI Helpline Number 1800 180 3024. A separate advisory (F.No. P.14019/01/2019-20 dated 28.03.2020) has been issued in this regard and is available on our website.
6. For further information you may reach to us at lab.ipc@gov.in.

We solicit your support in IPC's efforts to respond to the public health crisis due to COVID-19.

Sd/-

(Dr. Jai Prakash)

Secretary-cum-Scientific Director (I/c)

Copy for information to. Dr. Mandeep K. Bhandari, Joint Secretary (R), MoH&FW, Nirman Bhawan, New Delhi 110011.